secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0001193125-23-169038
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian shareholders approve 2M share increase to 2016 Equity Plan at annual meeting
--------------------------------------------------------------------------------

- Stockholders approved amendment to 2016 Equity Incentive Plan, increasing share reserve by 2,000,000 shares.
- Elected Tomas Kiselak and Jennifer K. Moses as Class II directors to serve until 2026.
- Ratified KPMG as independent auditor for 2023 with 39,588,463 votes for.
- Advisory vote on NEO compensation passed with 22,946,964 for and 12,351,317 against.
- Total shares outstanding as of record date: 43,108,897.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523169038/0001193125-23-169038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523169038/d521711d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-169038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer